This study is testing a drug called **lebrikizumab** for people with **moderate atopic dermatitis**, also known as eczema. Eczema causes dry, itchy patches on the skin. The study aims to see how well lebrikizumab helps reduce these itchy spots. Participants will be involved for about **38 weeks** (almost 9 and a half months), with **24 weeks** (6 months) of actual treatment. **Eligibility**: To join, you must have had eczema for at least a year, with 10-25% of your body affected. Your itch level must be 6 or higher on a 10-point scale. You should have tried other treatments that didn’t work well. If you're between 12 and 18 years old, you must weigh at least 40 kilograms (about 88 pounds). **Key Points**: - **Duration**: The study lasts for about 9 and a half months. - **Treatment**: 6 months of taking lebrikizumab. - **Eligibility**: Must have moderate eczema and tried other treatments. Before joining, consider if you meet the requirements and are comfortable with the study length.